%0 Case Reports
%T Initial experience of enfortumab vedotin in a patient with metastatic urothelial carcinoma on hemodialysis: Two case reports.
%A Mori S
%A Matsuo T
%A Honda H
%A Araki K
%A Mitsunari K
%A Ohba K
%A Mochizuki Y
%A Imamura R
%J IJU Case Rep
%V 7
%N 4
%D 2024 Jul
%M 38966765
暂无%R 10.1002/iju5.12736
%X <B>UNASSIGNED: </B>Few studies have reported on administering enfortumab vedotin to patients with metastatic urothelial carcinoma and end-stage renal disease requiring hemodialysis.<BR><B>UNASSIGNED: </B>Case 1: An 85-year-old man underwent hemodialysis for progressive renal failure 4 months after right laparoscopic radical nephroureterectomy. Case 2: A 73-year-old man underwent hemodialysis after two laparoscopic radical nephroureterectomies for recurrent urothelial carcinoma. In both cases, enfortumab vedotin was administered due to postoperative recurrence and progression despite platinum-based chemotherapy and pembrolizumab. Partial response and disease progression were observed in cases 1 and 2, respectively. Adverse events included a mild skin rash in both patients and neutropenia in Case 1, both of which resolved with symptomatic treatment.<BR><B>UNASSIGNED: </B>The efficacy and safety of enfortumab vedotin in patients with metastatic urothelial carcinoma, and end-stage renal disease undergoing hemodialysis, were confirmed.